Saiba
Saiba Biotech is a pioneering company focused on developing innovative vaccine technologies, including vaccines for peanut allergy and COVID-19. They utilize proprietary platform technologies such as virus-like particles (VLP) to create effective immunotherapies. The company's mission is to advance health through cutting-edge biotech solutions, aiming to bring new vaccines to market for various immune conditions.
Industries
Nr. of Employees
small (1-50)
Patents
Products
COVID-19 VLP-based vaccine candidate
A vaccine candidate based on an immunologically optimized virus-like particle platform that demonstrated preclinical induction of neutralizing antibodies in animal models.
Peanut allergy VLP-based vaccine candidate
A VLP-based vaccine candidate developed for peanut allergy that progressed to partnered clinical development and whose clinical advancement was referenced in partner IND filings.
COVID-19 VLP-based vaccine candidate
A vaccine candidate based on an immunologically optimized virus-like particle platform that demonstrated preclinical induction of neutralizing antibodies in animal models.
Peanut allergy VLP-based vaccine candidate
A VLP-based vaccine candidate developed for peanut allergy that progressed to partnered clinical development and whose clinical advancement was referenced in partner IND filings.
Services
Out-licensing platform technology and establishing collaborative agreements with external developers to broaden application of the platform.
Design and execution of preclinical vaccine studies in animal models, including immunogenicity and biomarker assessments.
Coordination with contract development and manufacturing partners for development and production of vaccine candidates.
Execution and analysis of ex vivo biomarker studies to assess immunological responses to vaccine candidates.
Out-licensing platform technology and establishing collaborative agreements with external developers to broaden application of the platform.
Design and execution of preclinical vaccine studies in animal models, including immunogenicity and biomarker assessments.
Coordination with contract development and manufacturing partners for development and production of vaccine candidates.
Execution and analysis of ex vivo biomarker studies to assess immunological responses to vaccine candidates.
Expertise Areas
- VLP-based vaccine platform development
- Preclinical immunology and vaccine R&D
- Vaccine process development and CDMO coordination
- Technology licensing and partnership management
Key Technologies
- Virus-like particle (VLP) vaccine platform
- Animal immunogenicity and neutralization assays
- Ex vivo biomarker assays
- CDMO-enabled process development and scale-up
News & Updates
Allergy Therapeutics announces FDA clearance of IND application for a novel peanut allergy vaccine candidate, paving the way for a Phase I PROTECT trial in H1 2022. Topline data from the first-in-human trial is expected in H1 2023.
UK biotech Allergy Therapeutics announced plans to test its peanut allergy vaccine in human clinical trials, bringing the world closer to a vaccine for peanut allergy.
Saiba AG has decided to focus on optimizing its COVID-19 vaccine candidate rather than rushing into clinical studies in 2020.
Allergy Therapeutics has licensed VLP technology from Saiba AG to explore its potential in oncology and immune conditions, building on progress in peanut allergy vaccine development.
Saiba AG has utilized its proprietary technology to develop a COVID-19 vaccine candidate with preclinical proof-of-concept.
Saiba AG has developed a platform technology based on immunologically optimized virus-like particles, establishing preclinical proof-of-concept for a COVID-19 vaccine candidate that induces high levels of neutralizing antibodies in test animals.
Allergy Therapeutics announces FDA clearance of IND application for a novel peanut allergy vaccine candidate, paving the way for a Phase I PROTECT trial in H1 2022. Topline data from the first-in-human trial is expected in H1 2023.
UK biotech Allergy Therapeutics announced plans to test its peanut allergy vaccine in human clinical trials, bringing the world closer to a vaccine for peanut allergy.
Saiba AG has decided to focus on optimizing its COVID-19 vaccine candidate rather than rushing into clinical studies in 2020.
Allergy Therapeutics has licensed VLP technology from Saiba AG to explore its potential in oncology and immune conditions, building on progress in peanut allergy vaccine development.
Saiba AG has utilized its proprietary technology to develop a COVID-19 vaccine candidate with preclinical proof-of-concept.
Saiba AG has developed a platform technology based on immunologically optimized virus-like particles, establishing preclinical proof-of-concept for a COVID-19 vaccine candidate that induces high levels of neutralizing antibodies in test animals.